Cardiff-based biotechnology company Antiverse has raised $9.3 million in Series A to scale its AI-powered therapeutic antibody discovery tools and advance lead programmes towards in-patient studies. The round was led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, and existing backers including DBW, Kadmos Capital and & Biotech Fund. The funds are intended to use machine learning and advanced computational design to identify challenging targets like G-protein coupled receptors and ion channels. Potential customers include pharmaceutical and biotech companies seeking to accelerate early discovery phases in areas where molecular targets have historically resisted biologic modulation. This is Antiverse's first institutional growth round beyond seed injections.